Fig. 6

Co-targeting CD47 and VEGF elicited synergetic anti-tumor effects in NSCLC. a In A549 xenograft model, tumor volume was presented. After treatment with VEGFR1-SIRPα or VEGFR1-Fc plus SIRPα-Fc, tumor weight was shown (mean ± SD, N = 5 per group). b In NCI-H1975 xenograft model, tumor volume was measured. After treatment with VEGFR1-SIRPα or VEGFR1-Fc plus SIRPα-Fc, tumor weight was shown (mean ± SD, N = 5 per group). c Representative image of immunohistochemistry CD31 staining of NCI-H1975 xenograft tumor tissues. d The relative vessels density of NCI-H1975 tumor or LLC tumor tissues. NS: no significance; ** P < 0.01